Add Yahoo as a preferred source to see more of our stories on Google. The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients ...
Newly FDA-approved doravirine/Islatravir maintained HIV suppression in phase 3 trials with comparable safety and minimal ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Only two people taking twice-yearly lenacapavir in a ...
Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given. HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS ...
Hosted on MSN
MSD progresses once-monthly HIV PrEP into Phase III
MSD is advancing its once-monthly oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) to Phase III trials. Announced at the International AIDS Society (IAS) 2025 conference ...
Merck is carving out its own place in the evolving HIV treatment space with an FDA approval for its Idvynso, a combination ...
Meeting UNAIDS’ “95/95/95” targets for 2025—95% of people with HIV knowing their status, 95% of those who know their status on treatment, and 95% of people on treatment having a suppressed viral ...
June 21 (UPI) --The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States plans to phase them out next year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results